SOURCE: Gene Express, Inc.

November 29, 2007 08:30 ET

Gene Express Announces Scientific Advisory Board

TOLEDO, OH--(Marketwire - November 29, 2007) - Gene Express, Inc. today announced that it has appointed the first two members of its Scientific Advisory Board to include Dr. David Sidransky, M.D. and Michael N. Liebman, Ph.D.

Gerald Vardzel, CEO of Gene Express, stated, "We are honored to have recruited such an outstanding team of internationally recognized experts in the study of cancer, genetics and molecular medicine. The wealth of experience and expertise of this board will be invaluable to ensure a solid development plan is in place for Gene Express's StaRT-PCR™ technology. From a strategic point of view, this group provides us with strong clinical research and practice perspectives, both for our current and future products intended for enhancing and accelerating the delivery of molecular diagnostics."

David Sidransky, M.D., renowned oncologist and a consultant to a number of leading biotechnology companies, is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. In addition, he is Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. He has served as a director of ImClone since January 2004. Dr. Sidransky is a founder of numerous biotechnology companies, and holds a number of biotechnology patents. He is serving and has served on scientific advisory boards of many private and public companies, including MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company). Dr. Sidransky is Vice Chairman of Alfacell Inc., and serves as Director of the American Association of Cancer Research (AACR). He has over 300 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters. He is the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the AACR.

Michael N. Liebman, Ph.D. is the Managing Director of Strategic Medicine, Inc. and is also a Senior Institute Fellow at the Windber Research Institute after serving as its Executive Director since November 2003. Previously, he was Director of Computational Biology and Biomedical Informatics at the Abramson Family Cancer Research Institute of the University of Pennsylvania Cancer Center. He served as Global Head of Computational Genomics at Roche Pharmaceuticals, and Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals. In addition, he was Director of Genomics for Vysis, Inc. and Director of Bioinformatics at the Amoco Technology Company. He has served on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics. He serves on 12 international scientific advisory boards, consults for 5 pharma/biotech companies and has been on the economic development programs in the Philadelphia Life Sciences Sector and the State of Illinois Biotechnology Commission. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and is currently Chair of the Healthcare Task Force for the SMART program, and is on the Human Health and Medicinal Chemistry Commission of the IUPAC. His research focuses on computational models of disease progression stressing risk detection, disease process modeling and analysis of lifestyle interactions.

Dr. Liebman commented, "It's exciting to join Gene Express's Scientific Advisory Board and be part of new approaches to problems that have existed for a long time, but have yet to be solved. This is critical to making a difference at the research level, as well as the care for patients in the future of medicine."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information